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a b s t r a c t
In mice persistently infected since birth with the prototypic arenavirus lymphocytic choriomeningitis
viurs, viral antigen and RNA are readily detected in most organs and cell types but remarkably absent in
skeletal muscle. Here we report that mouse C2C12 myoblasts that are readily infected by LCMV, become
highly refractory to LCMV infection upon their differentiation into myotubes. Myotube's resistance to
LCMV was not due to an intracellular restriction of virus replication but rather an impaired cell entry
mediated by the LCMV surface glycoprotein. Our ﬁndings provide an explanation for the observation that
in LCMV carrier mice myotubes, which are constantly exposed to blood-containing virus, remain free of
viral antigen and RNA despite myotubes express high levels of the LCMV receptor alpha dystroglycan and
do not pose an intracellular blockade to LCMV multiplication.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Arenaviruses are enveloped viruses with a bi-segmented,
negative-strand RNA genome and a life cycle restricted to the cell
cytoplasm. Each genome RNA segment, S and L, uses an ambisense
coding strategy to direct the expression of two viral polypeptides
in opposite orientation, separated by a non-coding intergenic
region. The S segment encodes the viral nucleoprotein (NP) and
the glycoprotein precursor, GPC that is processed by the cellular
site 1 protease to generate the mature virion surface glycoproteins,
GP1 and GP2. Trimers of GP1/GP2 form the spikes that decorate
the virus surface and mediate virus cell entry via receptor-
mediated endocytosis. The L segment encodes the viral RNA
dependent RNA polymerase, L protein, and the small RING ﬁnger
protein, Z, which is the counterpart of the matrix protein found in
many enveloped negative strand RNA viruses (Buchmeier et al.,
2007).
Arenaviruses cause chronic infections of rodents across the
world and can infect humans through mucosal exposure to
aerosols or by direct contact of abraded skin with infectious
material (Buchmeier et al., 2007). Arenaviruses merit interest as
both important human pathogens and experimentally highly
tractable model systems to study acute and persistent viral
infections. Both viral and host factors contribute to a variable
outcome of arenavirus infection, ranging from virus control and
clearance by the host defenses to chronic infection in the absence
of clinical symptoms to severe disease (Buchmeier et al., 2007).
Several arenaviruses, chieﬂy Lassa (LASV) and Junin (JUNV) viruses
cause hemorrhagic fever (HF) disease in humans and pose an
important public health problem in their endemic regions (Bray,
2005; Buchmeier et al., 2007; Geisbert and Jahrling, 2004). On the
other hand, studies with LCMV in its natural reservoir, the mouse,
have led to major concepts in virology and immunology that
apply universally to other viral infections, including virus-
induced immunopathology and MHC restriction (Oldstone, 2002;
Zinkernagel, 2002), as well as the contribution to viral persistence
of negative immune regulators like PDL-1 (Barber et al., 2006;
Brooks et al., 2006) and immune stimulatory molecules (Harker
et al., 2011; Yi et al., 2009).
Arenaviruses, including LCMV, are maintained in their natural
hosts via vertical transmission and a lifelong chronic infection that
is associated with relatively high levels of virus replication in
many cell types, a situation that can be recreated by LCMV
infection of newborn mice (Hotchin and Cinits, 1958). Replication
of the LCMV genome RNA should result in the generation of
variety of Pathogen-Associated Molecular Patterns (PAMPs)
including double-stranded (ds)RNA, uncapped 50-triphosphate,
small RNA species and single-stranded (ss)RNA molecules that
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could be recognized by different Pattern Recognition Receptors
(PRRs) including both membrane associated Toll-like receptors
(TLR) 3 and 7 and cytoplasmic RIG-I-like receptors (RLRs) RIG-I
and MDA5 (Borrow et al., 2010). Activated RIG-I and MDA5
(Habjan et al., 2008; Marq et al., 2011, 2010) associate with the
IPS-1 (a.k.a. MAVS) adapter (Kumar et al., 2006) to promote
activation of the non-classical IKK-related kinases TBK-1 and
IKKε that activate IRF3 and NF-κB, which together with ATF2/c-
JUN induce production of IFNβ that following interaction with its
receptor (IFNAR) leads to activation of the JAK/STAT signaling
pathway inducing the expression of hundreds of type I interferon
(IFN-I) stimulated genes (ISGs), to produce a cellular antiviral
state (Weber and Haller, 2007). Nevertheless, only modest
plasma levels of IFN-I are detected in mice persistently infected
with LCMV since birth (Bukowski et al., 1983; Kunz et al., 2006),
suggesting that similarly to many other viruses (Weber and
Haller, 2007), arenaviruses have developed ways to modulate
the host IFN-I response to promote their persistence (King et al.,
1992; Pircher et al., 1989). Accordingly, we documented that
LCMV NP is a potent anti-IFN-I viral factor (Martinez-Sobrido
et al., 2009, 2007, 2006), which likely contributes to facilitate the
LCMV carrier state in mice.
Early studies documented that in mice persistently infected
with LCMV since birth, viral antigen was detected in many
different cell types (Accinni et al., 1978; Doyle and Oldstone,
1978; Klavinskis and Oldstone, 1987; Nathanson et al., 1975;
Popescu et al., 1979; Rodriguez et al., 1985). Likewise, in these
mice viral RNA was readily detected in most tissues but remark-
ably absent in skeletal muscle (Fazakerley et al., 1991). This
observation led to suggest that myotubes lacked the cell entry
receptor used by LCMV. However, subsequent studies identiﬁed
α-dystroglycan (αDG), which is expressed at high levels in skeletal
muscle (Ibraghimov-Beskrovnaya et al., 1993), as a primary recep-
tor of Old World arenaviruses including LCMV and LASV (Cao et al.,
1998), which raised new questions about the mechanisms under-
lying the lack of skeletal muscle infection in LCMV carrier mice. To
investigate this issue we used LCMV infection of C2C12 cells, a
well-established cell system to study differentiation of myoblasts
into myotubes (Blau et al., 1983; Yaffe and Saxel, 1977). Here we
document that C2C12 myoblasts are readily infected by LCMV, but
following their differentiation into myotubes become highly
refractory to LCMV infection. Since the LCMV receptor αDG is
expressed at high levels on C2C12 myotubes, we reasoned that
myotubes restricted a post cell entry step of the LCMV life cycle.
Differentiation of C2C12 myoblasts into myotubes is associated
with expression of high levels of micro RNAs (miRNAs) 1, 133 and
206 that are also speciﬁcally expressed at high levels in skeletal
muscle cells in vivo (Luo et al., 2013; van Rooij et al., 2008).
Notably, inspection of the LCMV genome sequence revealed the
presence within the cording region of the LCMV L mRNA of miRNA
targeting sequences (miRTS) for miRNA-1, 133 and 206. However,
over-expression of each one of these miRNAs in 293T cells did not
affect multiplication of LCMV. C2C12 myoblasts persistently
infected with LCMV expressed high levels of viral antigen that
was not affected by their subsequent differentiation into myo-
tubes, indicating that the myotube intracellular milieu does not
restrict LCMV replication and viral gene expression. We found that
a recombinant LCMV where the VSV glycoprotein G substituted for
the LCMV GPC (rLCMV/VSVG) efﬁciently infected C2C12 myotubes.
Likewise, a recombinant VSV where LCMV GPC substituted for VSV
G (rVSV/LCMVGPC) was severely impaired in its ability to infect
C2C12 myotubes. We obtained similar results with human myo-
tubes. Our ﬁndings indicate that although skeletal muscle cells
express high levels of the bona ﬁde LCMV receptor αDG, they are
refractory to LCMV infection due to an impaired LCMV GPC-
mediated cell entry.
Results
LCMV infection of C2C12 cells
Mouse C2C12 cells have been widely used to investigate
differentiation of myoblasts into myotubes (Blau et al., 1983;
Yaffe and Saxel, 1977). During the ﬁrst four days of incubation in
the differentiation medium (DMEM containing 2% horse serum-
HS-), C2C12 cells fuse and form long-ﬁber shape multinuclear
myotubes. C2C12 myotubes accurately recreate many aspects of
bona ﬁde myotubes including morphology and protein and RNA
expression proﬁles (Burattini et al., 2004; Yoshida et al., 1998).
To examine whether C2C12 myoblasts and myotubes exhibited
different susceptibilities to LCMV infection, we infected non-
differentiated (myoblasts) and differentiated (myotubes) C2C12
with rARM and rCl-13 and at 16 h p.i. we examined the degree of
LCMV infection by detecting virus NP expression by immunoﬂuor-
escence (IF). Differentiation of C2C12 myoblasts produces a cell
population that contains 40–60% myotubes together with myo-
blasts that remain non-differentiated, hence differences in sus-
ceptibility between C2C12-derived myotubes and their myoblast
precursors to LCMV infection cannot be assessed by determining
production of LCMV infectious progeny. Strong LCMV NP expres-
sion was observed in both rARM and rCl-13 infected C2C12
myoblasts (Fig. 1A). In contrast, infection with rARM or rCl-13 of
C2C12 myoblasts grown for four days in DMEM with 2% HS to
promote differentiation into myotubes resulted in expression of
NP predominantly in C2C12 myoblast (arrow heads), whereas
C2C12 myobtubes were highly refractory to infection (Fig. 1B).
Effect on LCMV multiplication of miRNAs that are expressed at high
levels in skeletal muscle cells
To examine the effect of miRNA-1, 133a and 206 on LCMV
multiplication we used LCMV to infect (moi¼0.001) 293T cells
that also over-expressed, via transfection, miRNA-1, 133a or 206
and monitored production of infectious progeny at 24 h p.i. We
ﬁrst conﬁrmed the functionality of miRNA-1, 133 and 206 under
our experimental conditions. For this we co-transfected 293T cells
with a plasmid expressing each of the miRNAs and a plasmid
expressing Fireﬂy luciferase (FL) whose 30-UTR contained the
corresponding miRTS. A plasmid expressing Renilla luciferase
(RL) was used to normalize transfection efﬁciencies (Fig. 2A). Each
miRNA tested affected speciﬁcally only expression of the FL that
contained the matched miRTS. None of the tested miRNAs had a
noticeable effect on LCMV multiplication in 293T cells (Fig. 2B).
LCMV replication and gene expression in C2C12 myotubes
We next asked whether LCMV could replicate and express its
genome in the context of the myotube gene expression program.
For this, we took advantage of the non-cytolytic properties of
LCMV to establish LCMV-persistently infected C2C12 myoblasts
that were subsequently subjected to the differentiation protocol.
The majority of C2C12 myoblasts infected with rCl-13 expressed
viral antigen at four days post-infection (Fig. 3B). rCl-13 persis-
tently infected C2C12 myoblasts were differentiated for four days
and viral antigen expression assessed by IF. NP expression was
observed in both myoblasts and myotubes (arrows) (Fig. 3C),
suggesting that LCMV is able to replicate and express its genome
in C2C12 myotubes. Differentiated C2C12 cells contain a mixture of
myoblasts and myotubes and therefore we could not rule out that
infectious LCMV progeny being continuously generated by infected
C2C12 myoblasts could overcome an otherwise restricted LCMV
replication in C2C12 myotubes. To rule out this possibility, we used
a single-cycle infectious rLCMV that lacks the GPC gene but are
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pseudotyped with the GPC of Cl-13 strain (rCl-13ΔGPC/Cl-13GPC)
(Rodrigo et al., 2011). C2C12 myoblasts were highly susceptible to
rCl-13ΔGPC/Cl-13GPC (Fig. 4B). Infection of differentiated C2C12
cells with rCl-13ΔGPC/Cl-13GPC resulted in strong NP expression
in myoblasts (arrow heads), but negligible levels of NP were
observed in myotubes (Fig. 4C, After). In contrast, when C2C12
cells were infected with rCl-13ΔGPC/Cl-13GPC before differentia-
tion, NP expression was readily detected in both myoblasts and
myotubes (arrows). Since rCl-13ΔGPC/Cl-13GPC-infected cells can-
not generate infectious progeny, NP expression in C2C12 myotubes
indicated that persistent LCMV replication was compatible with
the myotube gene expression program.
Resistance of C2C12 myotubes to LCMV infection is mainly
determined by an impaired LCMV GPC-mediated cell entry
As LCMV was able to replicate and express its genome in C2C12
myotubes, we reasoned that restricted LCMV infection of myo-
tubes was related to a blockade of one of the multiple processes
involved in virus cell entry. To separate cell entry from other steps
of the LCMV life cycle, we examined infection of C2C12 cells with a
recombinant VSV expressing either its homologous surface glyco-
protein G (rVSV-WT), or the GPC of Cl-13 strain (rVSV/Cl-13GPC)
(Rojek et al., 2008a). C2C12 myoblasts were infected with either
rVSV-WT or rVSV/Cl-13GPC and 7 h later, infected cells were ﬁxed
and viral gene expression assessed by IF using an antibody to VSV
N. We observed strong VSV N expression in both rVSV-WT- and
rVSV/Cl-13GPC-infected C212 myoblasts (Fig. 5A, pre-differentia-
tion). We then subjected C2C12 myoblasts to differentiation for
four days prior infected them with either rVSV-WT or rVSV/Cl-
13GPC and 7 h later we assessed viral gene expression by IF.
We observed strong VSV-N expression in rVSV-WT-infected C2C12
myoblasts (arrow heads) and myotubes (arrows), suggesting that
in contrast to LCMV infection, C2C12 myotubes are susceptible to
VSV infection. Remarkably, rVSV/Cl-13GPC predominantly infected
C2C12 myoblasts (arrow heads) with VSV-N expression in C2C12
myotubes being hardly detectable (Fig. 5A, post-differentiation),
suggesting that LCMV GPC-mediated cell entry was restricted in
C2C12 myotubes. We also conducted the complementary experi-
ment using a rLCMV where VSV G substituted for LCMV GPC (rCl-
13/VSVG) to infect C2C12 cells. C2C12 myoblasts were highly
susceptible to rCl-13/VSVG (Fig. 5B, pre-differentiation). Notably,
C2C12 myotubes (arrows) were also very susceptible to rCl-13/
VSVG (Fig. 5B, post-differentiation).
C2C12 myotubes express high levels of isoform 3 of caveolin
(cav-3), and the interaction of cav-3 with DG in myotubes (Kogo et
al., 2006) could affect the caveolin-independent cell entry process
used by LCMV. To examine this possibility we evaluated whether
C2C12 myoblasts overexpressing cav-3 became refractory to LCMV
infection. For this we transduced C2C12 myoblasts with recombi-
nant adenoviruses expressing either GFP or cav-3 (Tsutsumi et al.,
2008) and subsequently infected them with LCMV (Fig. 6).
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Fig. 1. Differentiation of C2C12 cells into myotubes is associated with resistance to LCMV infection. (A) C2C12 cells were seeded in 24-well plates onto cover slips
(3.5104 cells per well) and cultured overnight. Next day, cells were infected with rARM or rCl-13 using 1105 FFU per well or remained uninfected (mock). At 16 h p.i.,
cells were ﬁxed with 4% PFA and expression of NP detected by IF using a rat monoclonal ab against LCMV NP (VL-4). Nuclei were detected by DAPI. (B) C2C12 cells prepared
as in (A) were placed in DMEM containing 2% HS and cultured for four days to allow for their differentiation into myotubes prior infection with either rArm or rCl-13 using
1105 FFU per well. At 16 h p.i., infected cells were ﬁxed with 4% PFA and expression of NP and myosin heavy chain (MyosinH) detected by IF using the rat MAb VL-4 to NP
and mouse Mab MF20-488 to MyosinH, respectively. Nuclei were detected by DAPI staining. Arrowheads indicate the C2C12 myoblasts expressing LCMV NP. Bars: 100 μm.
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Overexpression of cav-3 or GFP in C2C12 myoblasts did not affect
their susceptibility to LCMV infection as determined by detection
of NP antigen.
LCMV infection of human myotubes
To assess whether restricted LCMV GPC-mediated infection of
myotubes was a rather species-speciﬁc phenotype we examined
LCMV infection of human myotubes. Human derived myoblasts
can be differentiated to myotubes in a similar way as C212
myoblasts (Blau and Webster, 1981; Gaster et al., 2001; Henry et
al., 1995). We infected human myoblasts, prior or after differentia-
tion into myotubes, with rARM, rCl-13 and rCl-13/VSVG and 16 h
later, viral protein expression observed by IFA. rARM and rCl-13
infected very efﬁciently human myoblasts (arrow heads), whereas
human myotubes were highly refractory to these viruses (Fig. 7A).
In contrast, rCl-13/VSVG infected very efﬁciently both human
myoblasts and myotubes (arrows). To further conﬁrm that
restricted LCMV infection of human myotubes was related to a
cell entry blockade we used rVSV-WT and rVSV/Cl-13GPC to infect
human myoblasts or myotubes. Human myoblasts and myotubes
were susceptible to rVSV-WT (arrows Fig. 7B), whereas only
human myoblasts (arrow heads) were readily infected by rVSV/
Cl-13GPC (Fig. 7B).
Discussion
Viral antigen and RNA were conspicuously observed in most
tissues and cell types in LCMV carrier mice but notably absent in
skeletal muscle (Fazakerley et al., 1991). This ﬁnding motivated us
to investigate the reasons for the restricted multiplication of LCMV
in myotubes. To facilitate experimental work aimed at addressing
this question we used the C2C12 cells, a validated and widely used
cell system for the investigation of myoblasts differentiation
into myotubes (Blau et al., 1983; Yaffe and Saxel, 1977). Non-
differentiated (myoblasts) C2C12 cells were very susceptible to
LCMV infection, whereas following their differentiation into myo-
tubes they became highly refractory to LCMV infection. Because
myotubes express high levels of the LCMV receptor αDG we
reasoned that the blockade was likely at a post cell entry step
of the LCMV life cycle. Differentiation of C2C12 myoblasts into
myotubes is associated with high expression levels of miRNA-1,
133 and 206 and intriguingly the corresponding miRTS were found
to be present within the coding region of the LCMV L mRNA,
raising the attractive possibility that targeting of LCMV L mRNA by
miRNA-1, 133 and 206 could contribute to LCMV restricted multi-
plication in myotubes, a ﬁnding that would be consistent with
several published studies showing a direct regulatory effect of
miRNAs on multiplication of a variety of animal viruses including
inﬂuenza (Ma et al., 2012; Song et al., 2010), picornavirus and
adenovirus (Barnes et al., 2008; Cawood et al., 2009; Kelly et al.,
2010, 2008; Ylosmaki et al., 2008). However, over-expression of
miRNA-1, 133 or 206 in 293T cells did not have any noticeable
effect on LCMV multiplication (Fig. 2), suggesting that highly
unlikely these miRNAs played a signiﬁcant role in the restricted
multiplication of LCMV in C2C12 myotubes. Consistent with these
results, we found that LCMV replication and gene expression were
not affected by the differentiation of LCMV persistently infected
C2C12 myoblasts into myotubes. It remains to be determined
whether miRTS for miRNA-1, 133 and 206 within the coding
region of the LCMV L mRNA are not accessible to miRNA targeting,
or whether LCMV can actively counteract the host miRNA-
mediated antiviral immunity.
The ﬁndings described above ability led us to consider that
although myotubes express high levels of the LCMV receptor αDG
(Ibraghimov-Beskrovnaya et al., 1993), their resistance to LCMV
infection might be related to impaired cell entry mediated by
LCMV GPC. Remarkably, we found that resistance and suscept-
ibility of C2C12 myotubes to LCMV and VSV infection, respectively,
was drastically inﬂuenced by the nature of the virus surface
glycoprotein, indicating that impaired LCMV GPC-mediated cell
entry critically contributed to myotube's resistance to LCMV
infection. DG is translated from a single mRNA and cleaved into
αDG and βDG that remain non-covalently associated (Barresi and
Campbell, 2006). αDG is an extracellular protein that binds to a
variety of extracellular ligands including laminin, agrin and perle-
can in muscle tissue (Bowe et al., 1994; Campanelli et al., 1994; Gee
et al., 1994; Sugiyama et al., 1994). On the other hand, βDG is a
transmembrane protein and associates with intracellular proteins
including dystrophin and nitric oxide synthase that connect αDG
and actin cytoskeleton in muscle tissue (Brenman et al., 1995;
Ervasti and Campbell, 1991; Grady et al., 1999; Jung et al., 1995;
Yoshida et al., 2000). LARGE-mediated glycosylation of αDG is
critical for αDG binding to its extracellular ligands, as well as to its
role as a functional receptor for LCMV (Hara et al., 2011; Kunz
et al., 2005). Extracellular ligands of αDG in C2C12 cells differentiated
into myotubes could potentially hamper the interaction between
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Fig. 2. Effect of over-expression of miRNA-1, 133a or 206 on LCMV multi-
plication. (A) Activity of miRNA-1, 133 and 206 in 293T cells. 293T cells seeded on
12-well plates at 4105 cells per well and cultured overnight were transfected
with the indicated combination and amounts of plasmids expressing miRNAs and
FL containing miRTS within its 30-UTR, together with a plasmid expressing RL to
normalize transfection efﬁciencies. At 36 h post-transfection cells lysates were
prepared for the Dual-Glo luciferase assay. Results represent the average and SD of
three independent experiments. (B) 293T cells were transfected with the indicated
miRNA-expressing plasmid (miRNA-all: miRNA-1, 133, and 206) and 24 h later
infected (moi¼0.001) with LCMV. Production of infectious progeny in tissue
culture supernatants was determined at 24 h p.i. Results represent the average
and SD of ﬁve replicates.
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αDG and GP1 of LCMV, thus interfering with LCMV infection of
myotubes. We did not perform studies examining possible differ-
ences in virus binding to C2C12 myoblasts versus C2C12 myotubes
because differentiation of C2C12 myoblasts into myotubes results
in a cell population that contains still a signiﬁcant percentage
(40–60%) of non-differentiating myoblasts, which would make
inconclussive results from biochemical assays done at the cell
population level. However, LCMV has been shown to be able to
compete with extracellular matrix ligands for αDG binding in muscle
cells (Han et al., 2009). In muscle cells DG bridges extracellular
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Fig. 3. LCMV multiplication and gene expression is not inhibited by the myotube gene expression program. (A) Schematic diagram of the experiment. Open arrows
indicate the time at which cells were ﬁxed. C2C12 cells were infected with rCl-13 (moi¼0.1). Three days later infected cells were seeded in 24-well plates onto cover slips
(3.5104 cells per well). Two days before (B) or four days after (C) starting differentiation by placing the cells in DMEMþ2% HS, cells were ﬁxed with 4% PFA and expression
of NP and MyosinH detected by IFA using MAb VL-4 and MF20-488, respectively. Nuclei were detected by DAPI staining. Arrows indicate C2C12 myotubes expressing LCMV
NP. Bars: 100 μm.
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(A) Schematic diagram of the experiment. Open arrows indicate times at which cells were ﬁxed and NP expression determined by IF. (B) C2C12 (myoblasts) were infected
with rCl-13ΔGPC/Cl-13GPC and at 16 h p.i. ﬁxed and examined for NP expression by IF using the VL-4 MAb to NP. Nuclei were identiﬁed by DAPI staining. (C) C2C12
myoblasts were seeded in 24-well plates onto cover slips (3.5104 cells per well). Two days before (Before) or four days after (After) starting differentiation into myotubes,
cells were infected with rCl-13ΔGPC/Cl-13GPC using 1105 FFU per well. At 24 h p.i., cells were ﬁxed with 4% PFA and stained with VL-4 and MF20-488 for the detection of
NP and myosin heavy chain, respectively. Nuclei were detected by DAPI staining. Arrows and arrowheads indicate C2C12 myotubes and myoblasts, respectively, expressing
LCMV NP. Bars: 100 μm.
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Fig. 5. Resistance of C2C12 myotubes to LCMV infection is mainly determined by an impaired LCMV GPC-mediated cell entry. C2C12 myoblasts were seeded in 24-well
plates onto cover slips (3.5104 cells per well). Two days before (pre-differentiation) or four days after (post-differentiation) starting differentiation into myotubes, cells
were infected with the indicated viruses. (A) Cells were infected with rVSV-WT or rVSV/Cl-13GPC using 1105 PFU per well. (B) Cells were infected with rCl-13 or rCl-13/
VSVG using 1105 FFU per well. At 7 h (rVSVs) or 16 h (rLCMVs) p.i., cells were ﬁxed with 4% FPA and stained with a MAb against VSV N protein (VSV-N), a rat MAb VL-4
(NP), and also, only post-differentiation, mouse MAb MF20-488 (MyosinH). Nuclei were detected by DAPI staining. Arrows and arrowheads indicate C2C12 myotubes and
myoblasts, respectively, expressing LCMV NP. Bars: 100 μm.
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Fig. 7. Human myotubes are resistant to LCMV infection. Human myoblasts were seeded on 96-well plates at 2104 cell per well. Two days before (pre-differentiation) or
four days after (post-differentiation) starting differentiation, cells were infected with the indicated viruses. (A) Cells were infected with rARM, rCl-13, or rCl-13/VSVG at
2.5104 FFU per well. (B) Cells were infected with rVSV-WT, or rVSV/Cl-13GPC at 1105 PFU per well. At 7 h (rVSVs) or 16 h (rLCMVs) p.i., cells were ﬁxed with 4% PFA and
stained with mouse MAbs to VSV N protein (VSV-N), LCMV NP (VL-4), or MyosinH (MF20-488). Nuclei were detected by DAPI staining. Arrows and arrowheads indicate
human myotubes and myoblasts, respectively, expressing viral proteins. Bars: 100 μm.
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ligands and intracellular proteins that associate with actin cytoske-
leton. These interactions form a solid complex and provide structural
stability to the sarcolemma during contraction. It is plausible that the
complex structure of which αDG form part in skeletal muscle could
pose a barrier for LCMV GPC-mediated cell entry.
Upon receptor binding, LCMV is internalized via receptor-
mediated endocytosis, which involves a pH-dependent fusion
event between viral and cellular membranes within the acidic
environment of the endosome (Borrow and Oldstone, 1994;
Castilla et al., 1994). The endocytic vesicles of the LCMV are non-
coated and LCMV cell entry process was reported to be
cholesterol-dependent but clathrin-, dynamin-, caveolin-, ARF6-,
ﬂotillin-, and actin-independent (Borrow and Oldstone, 1994;
Quirin et al., 2008; Rojek et al., 2008a, 2008b; Shah et al., 2006;
Vela et al., 2007). Recently, we reported that in A549 human cells
LCMV GPC-mediated cell entry is NHE-, actin-, and Pak1-depen-
dent, suggesting a contribution of macropinocytosis to cell entry of
LCMV (Iwasaki et al., 2014). These ﬁndings indicate that LCMV uses
a non-classic endocytic pathway that is distinct of the clathrin-
depending endocytic pathway used for cell entry by New World
arenaviruses, including JUNV (Geisbert and Jahrling, 2004;
Martinez et al., 2007; Rojek et al., 2008a, 2008b). It is plausible
that one of processes required for the endocytic pathway used by
LCMV is not operational in skeletal muscle, which could contribute
to restricted infection and this could be an explanation of the
resistance of muscle to LCMV infection. In this regard DG was
reported to be associated with the cav-3 isoform of caveolin in
C2C12 myotubes (Kogo et al., 2006), which could affect the
caveolin-independent cell entry process used by LCMV. However,
overexpression of cav-3 in C2C12 did not affect LCMV infection,
suggesting that it is highly unlikely that an interaction between
cav-3 and DG was responsible for the resistance of C2C12 myo-
tubes to LCMV infection.
Postnatal growth of skeletal muscle in mice is through hyper-
trophy and requires the participation of satellite cells, which are
skeletal muscle stem that within the ﬁrst few weeks after birth
continue to fuse to grow muscle ﬁbers (Cardasis and Cooper, 1975;
Knapp et al., 2006). Mice infected as newborns with LCMV develop
a chronic infection where viral antigen and RNA are readily
detected in most tissues and cell types but strikingly absent in
skeletal muscle. Differentiation of LCMV-infected C2C12 myoblasts
into myotubes did not affect expression levels of LCMV NP,
suggesting that a blockade imposed by the intracellular milieu of
myotybes is unlikely the reason for the lack of LCMV infection of
skeletal muscle cells. In adult mice satellite cells are in a resting
state and resume proliferation and differentiation to muscle cells
only in response to exercise or trauma induced damage (Charge
and Rudnicki, 2004; Seale et al., 2001). Myoblasts are thought to
be an active state of satellite cells and committed to become
myotubes (Charge and Rudnicki, 2004; Wozniak et al., 2005;
Zammit et al., 2006). In healthy muscle tissue of adult mice
satellite cells and myoblasts are present at very low numbers,
hence it may be rather difﬁcult to identify in LCMV carrier mice
potentially infected satellite cells and myoblasts. LCMV-infected
myoblasts in carrier mice have the potential to become muscle
cells that, based on our results with C2C12 cells, would allow virus
multiplication. However, in vivo differentiation of satellite cells
into myotubes would occur only under conditions that induce
muscle damage, which together with the low numbers of cells
involved would make it difﬁcult their detection. On the other
hand, the high viremia (103–105 PFU/ml in serum) in LCMV carrier
mice together with the existence of an extensive network of
capillaries that provide skeletal muscle cells with a large blood
ﬂow (1–4 ml/min per 100 g under resting conditions) would
predict an easy viral access to skeletal muscle cells. Our ﬁnding
that C2C12 myotubes are highly refractory to LCMV infection could
explain why although in LCMV carrier mice skeletal muscle cells
are constantly exposed to blood-containing virus they remain free
of viral antigen and RNA.
Conclusions
We have shown that C2C12 cells become highly resistant to
LCMV infection upon their differentiation into myotubes. We
presented evidence that LCMV replication and gene expression
was not restricted in C2C12 myotubes. However, despite the LCMV
receptor αDG is expressed at high levels in myotubes, LCMV GPC-
mediated cell entry was severely restricted. These ﬁndings can
explain why in LCMV carrier mice skeletal muscle cells remain free
of viral antigen and RNA.
Materials and methods
Cells
C2C12 mouse myoblasts were grown in GlutaMax Dulbecco's
modiﬁed Eagle's medium (DMEM) (Invitrogen) containing 10%
fetal bovine serum (FBS), 100 mg/ml streptomycin, and 100 U/ml
penicillin. To induce myogenic differentiation of C2C12 cells, cell
culture medium of a conﬂuent cell monolayer was replaced with
fresh medium with 2% horse serum (HS). Human myoblasts were
obtained from Lonza (Catalog# CC-2580) and grown in DMEM
(Invitrogen) containing 20% FBS, 2 mM L-glutamine, 10 μg/ml
insulin, 5.5 μg/ml transferrin, 6.7 pg/ml selenium (ITS, Life Tech-
nologies), 100 μg/ml ﬁbroblast growth factor, 500 μg/ml epidermal
growth factor, 100 mg/ml streptomycin, and 100 U/ml penicillin.
To induce myogenic differentiation of human myoblasts, cell
culture medium were replaced with DMEM containing 2% HS,
ITS, 2 mM L-glutamine, 100 mg/ml streptomycin, and 100 U/ml
penicillin. The cell culture medium for myoblasts and myotubes
was replaced every two days. BHK-21 and 293T cells were grown
in DMEM containing 10% FBS, 100 mg/ml streptomycin, and 100 U/ml
penicillin.
Generation and titration of viruses
Recombinant Armstrong (rARM) and Clone 13 (rCl-13) strains
of LCMV, as well as rLCMVs expressing GPC from vesicular
stomatitis virus (VSV) (rCl-13/VSVG) have been described
(Pinschewer et al., 2003). A rCl-13 lacking GPC and expressing
Gaussia luciferase (rCl-13ΔGPC/Cl-13GPC) was generated by
reverse genetics using procedures described (Rodrigo et al.,
2011). Brieﬂy, the open reading frame (ORF) of Gaussia luciferace
was ampliﬁed by PCR and substituted for the GPC ORF in pPOLI-S
plasmid to generate pPOLI-S NP/Gluc. To rescue rCl-13ΔGPC/Cl-
13GPC, we transfected BHK-21 cells with plasmids pPOLI-L (Cl-13
strain backbone) and pPOLI-S NP/Gluc that directed intracellular
pol1-mediated synthesis of recombinant L and S genome RNA
species, together with plasmids pC-L, pC-NP, and pC-LCMV cl-13
GP to provide the trans-acting factors NP and L and the surface
GP1/GP2 complex of Cl-13 strain of LCMV. Rescued virus present in
cell culture supernatant of transfected cells was ampliﬁed by
infecting BHK-21 cells transfected with pC-LCMV cl-13 GP to
obtain a high titer virus stock. Wild type rVSV (rVSV-WT) and
rVSV expressing GPC of LCMV Cl-13 strain (rVSV/Cl-13GPC) have
been described (Rojek et al., 2008a). Titers of rLCMVs and rVSVs
were determined by immunofocus (Battegay, 1993) and plaque
assay, respectively. Recombinant adenoviruses expressing either
GFP or cav-3 have been described (Tsutsumi et al., 2008).
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Expression and activity of miRNAs
Plasmids (pCxGb backbone) expressing miRNA-1, 133a or 206,
as well as plasmids (pSRlb backbone) expressing Fireﬂy luciferase
(FL) containing miRTS for miRNA-1þ206 and 133a within the
30UTR, were obtained from Dr. Yoshio Kato. To test the activity
of miRNA-1, 133a and 206 we transfected 293T cells seeded in
12-well plates at 4105 cells per well and cultured overnight with
pCxGb plasmids expressing each individual miRNA-1 (0.2 μg),
miRNA-133a (0.5 μg) or miRNA-206 (0.5 μg) together pSRlb plas-
mids expressing FL-miRTS-1þ026 (0.2 μg), FL-miRTS-133a
(0.2 μg), or FL control. A plasmid expressing Renilla luciferase
(RL) (0.1 μg) was incorporated into the transfection mix to normal-
ize transfection efﬁciencies. Transfections were done using lipo-
fectamine 2000 (2 μl/μg DNA). At 36 h post-transfection cell
lysates were prepared for the Dual-Glo luciferase assay (Promega).
Immunoﬂuorescence assay (IFA)
Mock- and virus-infected cells were ﬁxed with 4% paraformal-
dehyde (PFA) in phosphate-buffered saline (PBS). After cell per-
meabilization by treatment with 0.3% Triton X-100 in PBS
containing 3% bovine serum albumin (BSA), cells were stained
using an anti-NP rat monoclonal antibody (VL-4) and an Alexa
Fluor 568-labeled anti-rat secondary antibody, or an anti-VSV-N
mouse monoclonal antibody and an Alexa Fluor 568-labeled anti-
mouse secondary antibody. Myosin expression in differentiated
myotubes was detected by staining using an anti-myosin heavy
chain mouse monoclonal antibody conjugated with an Alexa Fluor
488 (MF20-488). Cav-3 expression was detected by staining using
an anti-cav-3 mouse monoclonal antibody and an Alexa Fluor 488-
labeled anti-mouse secondary antibody. Nuclei were detected by
40,6-diamidino-2-phenylindole (DAPI). Stained cells were observed
under a confocal microscope (LSM 710, Zeiss).
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